Complementary detection of genomic alterations in metastatic castration-resistant prostate cancer (mCRPC) from CheckMate 9KD through analyses of tumor tissue and plasma DNA.

被引：0
|
作者：
Sausen, Mark
Baden, Jonathan F.
Kalinava, Natallia
Wang, Xuya
Li, Jun
Anguiano, Esperanza
Unsal-Kacmaz, Keziban
Wind-Rotolo, Megan
Quinn, Katie
Green, George
机构：
[1] Bristol Myers Squibb, Princeton, NJ USA
[2] Guardant Hlth Inc, Redwood City, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.5038
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5038
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Circulating tumor DNA (ctDNA) identifies genomic alterations associated with resistance to Nivolumab in combination with other agents in metastatic castration-resistant prostate cancer from the CheckMate 9KD trial
    Wang, Yu
    Li, Jun
    Baden, Jonathan
    Gupta, Saurabh
    David, Justin M.
    CANCER RESEARCH, 2023, 83 (07)
  • [2] Efficacy and safety of nivolumab in combination with docetaxel in men with metastatic castration-resistant prostate cancer in CheckMate 9KD
    Fizazi, K.
    Gonzalez Mella, P.
    Castellano, D.
    Minatta, N.
    Kalebasty, A. Rezazadeh
    Shaffer, D.
    Vazquez Limon, J. C.
    Armstrong, A. J.
    Sanchez Lopez, H. M.
    Sharkey, B.
    Saci, A.
    Li, J.
    Wang, X.
    Ciprotti, M.
    Sathyanarayana, P.
    Saad, F.
    Petrylak, D. P.
    Retz, M. M.
    Pachynski, R. K.
    Drake, C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [3] Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial
    Fizazi, Karim
    Retz, Margitta
    Petrylak, Daniel P.
    Goh, Jeffrey C.
    Perez-Gracia, Jose
    Lacombe, Louis
    Zschabitz, Stefanie
    Burotto, Mauricio
    Mahammedi, Hakim
    Gravis, Gwenaelle
    Bastos, Diogo Assed
    McCune, Steven L.
    Limon, Juan Carlos Vazquez
    Kwan, Edmond M.
    Castellano, Daniel
    Flechon, Aude
    Saad, Fred
    Grimm, Marc-Oliver
    Shaffer, David R.
    Armstrong, Andrew J.
    Bhagavatheeswaran, Prabhu
    Amin, Neha P.
    Unsal-Kacmaz, Keziban
    Wang, Xuya
    Li, Jun
    Loehr, Andrea
    Pachynski, Russell K.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (08)
  • [4] CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) plus rucaparib for chemotherapy (CT)-naive metastatic castration-resistant prostate cancer (mCRPC)
    Petrylak, D. P.
    Perez-Gracia, J. L.
    Lacombe, L.
    Bastos, D. A.
    Mahammedi, H.
    Kwan, E. M.
    Zschaeitz, S.
    Armstrong, A. J.
    Pachynski, R. K.
    Goh, J. C.
    Burotto, M.
    Gravis, G.
    McCune, S. L.
    Vazquez Limon, J. C.
    Retz, M.
    Saad, F.
    Amin, N. P.
    Li, J.
    Unsal-Kacmaz, K.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2021, 32 : S629 - S630
  • [5] CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) plus rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC).
    Pachynski, Russell Kent
    Retz, Margitta
    Goh, Jeffrey C.
    Burotto, Mauricio
    Gravis, Gwenaelle
    Castellano, Daniel
    Flechon, Aude
    Zschaebitz, Stefanie
    Shaffer, David R.
    Limon, Juan Carlos Vazquez
    Grimm, Marc-Oliver
    McCune, Steven L.
    Amin, Neha P.
    Li, Jia
    Wang, Xuya
    Unsal-Kacmaz, Keziban
    Saad, Fred
    Petrylak, Daniel P.
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] An open-label, phase 2 study of nivolumab in combination with either rucaparib, docetaxel, or enzalutamide in men with castration-resistant metastatic prostate cancer (mCRPC; CheckMate 9KD).
    Fizazi, Karim
    Drake, Charles G.
    Shaffer, David R.
    Pachynski, Russell
    Saad, Fred
    Ciprotti, Marika
    Kong, George
    Ryan, Charles J.
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Nivolumab Plus Docetaxel in Patients With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Results From the Phase II Checkmate 9KD Trial
    Fizazi, K.
    Mella, P. Gonzalez
    Castellano, D.
    Minatta, J. N.
    Kalebasty, A. R.
    Shaffer, D.
    Limon, J. C. Vazquez
    Lopez, H. M. Sanchez
    Armstrong, A. J.
    Horvath, L.
    Bastos, D. A.
    Amin, N. P.
    Li, J.
    Unsal-Kacmaz, K.
    Retz, M.
    Saad, F.
    Petrylak, D. P.
    Pachynski, R. K.
    JOURNAL OF UROLOGY, 2023, 209 (02): : 445 - 446
  • [8] Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer
    Sonpavde, Guru
    Agarwal, Neeraj
    Pond, Gregory Russell
    Nagy, Rebecca J.
    Nussenzveig, Roberto H.
    Hahn, Andrew W.
    Sartor, Oliver
    Gourdin, Theodore Stewart
    Nandagopal, Lakshminarayanan
    Ledet, Elisa M.
    Naik, Gurudatta
    Armstrong, Andrew J.
    Wang, Jue
    Bilen, Mehmet Asim
    Gupta, Shilpa
    Grivas, Petros
    Pal, Sumanta K.
    Lanman, Richard B.
    Talasaz, AmirAli
    Lilly, Michael B.
    CANCER, 2019, 125 (09) : 1459 - 1469
  • [9] Correlation between genomic alterations and germline mutations in men with metastatic castration-resistant prostate cancer (mCRPC)
    Llacer Perez, C.
    Oliva Fernandez, L.
    Canada-Higueras, E.
    Saez, M. I.
    Villatoro, R.
    Montesa Pino, A.
    Herrera Imbroda, B.
    Hernandez, D.
    Lozano Mejorada, R.
    Romero Laorden, N.
    Marquez, M.
    Grau, G.
    Pineda, A.
    Lopez, F. J.
    Peinado, P.
    Alameda, D.
    Olmos, D.
    Castro, E.
    ANNALS OF ONCOLOGY, 2021, 32 : S641 - S642
  • [10] Plasma circulating tumor DNA (ctDNA) based clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC)
    Kohli, Manish
    Tan, Winston
    Zheng, Tiantian
    Wang, Amy
    Huo, Yelia
    Montesinos, Carlos
    Wong, Calvin
    Du, Pan
    Jia, Shidong
    Yu, Jianjun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345